BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31060392)

  • 1. Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
    Goyal RK; Carter GC; Nagar SP; Smyth EN; Price GL; Huang YJ; Li L; Davis KL; Kaye JA
    Curr Med Res Opin; 2019 Oct; 35(10):1699-1710. PubMed ID: 31060392
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
    Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
    Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.
    Li N; Hao Y; Xie J; Lin PL; Zhou Z; Zhong Y; Signorovitch JE; Wu EQ
    Curr Med Res Opin; 2015 Aug; 31(8):1573-82. PubMed ID: 26074049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study.
    Goyal RK; Chen H; Abughosh SM; Holmes HM; Candrilli SD; Johnson ML
    Cancer; 2023 Apr; 129(7):1051-1063. PubMed ID: 36760031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
    Poorvu PD; Vaz-Luis I; Freedman RA; Lin NU; Barry WT; Winer EP; Hassett MJ
    Breast Cancer Res Treat; 2018 Apr; 168(3):727-737. PubMed ID: 29332137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
    Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
    Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
    Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States.
    Goyal RK; Cuyun Carter G; Nagar SP; Nash Smyth E; Price GL; Parikh RC; Huang YJ; Li L; Davis KL; Kaye JA
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):699-710. PubMed ID: 32755262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
    Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
    Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
    Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
    Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
    BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.
    Lin PL; Hao Y; Xie J; Li N; Zhong Y; Zhou Z; Signorovitch JE; Wu EQ
    Cancer Med; 2016 Feb; 5(2):209-20. PubMed ID: 26686532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
    Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
    Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
    Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
    Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival in patients with HR+/HER2- metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study.
    Simon J; Chaix M; Billa O; Kamga AM; Roignot P; Ladoire S; Coutant C; Arveux P; Quantin C; Dabakuyo-Yonli TS
    Br J Cancer; 2020 Sep; 123(7):1071-1077. PubMed ID: 32678278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
    Guérin A; Hao Y; Tang D; Peeples M; Fang A; Kageleiry A; Koo V; Li N; Wu EQ
    Expert Opin Pharmacother; 2016 Jun; 17(9):1189-96. PubMed ID: 27052735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.
    Watanabe J; Hayashi T; Tadokoro Y; Nishimura S; Takahashi K
    Breast Cancer Res Treat; 2017 Dec; 166(3):911-917. PubMed ID: 28852946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.